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Background: Pituitary tumor-transforming gene (PTTG) is an oncogene that is overexpressed in variety of tumors
and exhibits characteristics of a transforming gene. Previous transgenic mouse models to access the tumorigenic
potential in the pituitary and ovary have resulted in dysplasia without formation of visible tumors, possibly due to
the insufficient expression of PTTG. PTTG expression level is critical for ovarian tumorigenesis in a xenograft model.
Therefore, the tumorigenic function of PTTG in vivo remains unclear. We generated a transgenic mouse that
overexpresses PTTG driven by the CMV promoter to determine whether PTTG functions as a transforming
oncogene that is capable of initiating tumorigenesis.
Methods: Transgenic animals were generated by microinjection of PTTG transgene into the male pronucleus of
FVB 0.5 day old embryos. Expression levels of PTTG in tissues of transgenic animals were analyzed using an
immunohistochemical analysis. H&E staining and immunohistostaining were performed to examine the type of
tumor in transgenic and PTTG transgenic/p53+/- animals.
Results: PTTG transgenic offspring (TgPTTG) were monitored for tumor development at various ages. H&E analysis
was performed to identify the presence of cancer and hyperplastic conditions verified with the proliferation marker
PCNA and the microvessel marker CD31. Immunohistochemistry was performed to determine transgene expression,
revealing localization to the epithelium of the fallopian tube, with more generalized expression in the liver, lung,
kidney, and spleen. At eight months of age, 2 out of 15 TgPTTG developed ovarian cancer, 2 out of 15 developed
benign tumors, 2 out of 15 developed cervical dysplasia, and 3 out of 15 developed adenomyosis of the uterus. At
ten months of age, 2 out of 10 TgPTTG developed adenocarcinoma of the ovary, 1 out of 10 developed a papillary
serous adenocarcinoma, and 2 out of 10 presented with atypia of ovarian epithelial cells. Tumorigenesis is a
multi-step process, often requiring multiple oncogenes and/or inactivation of tumor suppressor genes. Therefore, to
understand the contribution of p53 to PTTG induced tumorigenesis, we crossbred TgPTTG to p53+/− mice and
maintained those 8 to 10 months. TgPTTG/p53+/− animals developed sarcomas faster than p53+/− alone as well as
different tumor types in addition to cervical carcinomas in situ in 10 out of 17 females.
Conclusions: We conclude that while PTTG is a functional transforming oncogene, it requires an additional partner
to effectively promote tumorigenesis through the loss of p53 include or between function or modulation.
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The pituitary tumor transforming gene (PTTG), also
known as securin, is ubiquitously expressed at a low
basal level where it functions in regulating sister chro-
matid separation [1]. Its physiologic functions include
cell proliferation, ensuring the fidelity of DNA replica-
tion, DNA damage repair, organ development, and me-
tabolism [2]. Overexpression of PTTG influences
multiple pathways for cancer initiation and progression
including enhanced cell proliferation [3], genomic in-
stability [4], and cellular transformation [3,5]. Its trans-
forming ability has been demonstrated in vitro where
over-expression of PTTG induces anchorage-independent
growth in soft agar and in vivo xenograft tumor formation
in nude mice using rat fibroblast NIH3T3 cells and
human embryonic kidney HEK293 cells [3,5]. PTTG over-
expression has been correlated with the promotion of
angiogenesis through increased expression and secretion
of several factors including basic fibroblast growth factor
(bFGF), vascular endothelial growth factor (VEGF), and
interleukin 8 (IL-8) [3,6,7]. PTTG is implicated in metas-
tasis through the induction of the epithelial to mesenchy-
mal transition [8,9].
PTTG overexpression has been identified in a variety
of endocrine-related tumors, including pituitary, ovarian,
uterine, breast, and thyroid [5,6,10,11] and non-
endocrine related tumors such as lung, gastrointestinal,
and gliomas. PTTG expression is also detected in germ
cell tumors, sex-cord and stromal cell tumors, epithelial
tumors arising from the ovary and in multiple types of
breast cancer, including invasive ductal carcinomas,
ductal in situ carcinomas, and infiltrating ductal carcin-
omas [11]. In pituitary adenomas, PTTG is implicated in
tumor initiation and progression [12]. It has also been
identified as an oncogene in pituitary tumors activated
in the early stages of cellular transformation, from nor-
mal to hyperplastic [13], and has been correlated with
tumor invasiveness [6]. Levels of PTTG expression have
also been correlated to the degree of malignancy, patho-
genesis, and progression of colorectal, thyroid, and
breast tumors [14-16]. In the case of gliomas, PTTG has
been correlated to poor prognosis in patients [17].
PTTG is abundantly expressed in several carcinoma cell
lines including cervical carcinoma HeLa cells, choriocar-
cinomas JEG-3 and JAR, breast adenocarcinoma MCF-7,
osteogenic sarcoma U-2OS, hepatocellular carcinoma
Hep 3B, lung carcinoma H1299, EY and A549, ovarian
CAOV3 and A2780, and thyroid carcinoma TC-1 [18,19].
These finding indicate that PTTG may be involved in
transformation of several tissues leading to tumorigenesis.
Transgenic PTTG−/− mice exhibit pituitary hypoplasia
and, upon cross-breeding with heterozygous deletion of
retinoblastoma (Rb+/−), show a tumor development rate
of 30%. Comparatively Rb+/−/PTTG+/+ develop tumorsat 86% by 13 months of age [20]. PTTG silencing using
siRNA on xenograft tumors from an ovarian cancer cell
line and hepatocellular carcinoma cell line reduced both
the size and incidence of tumor burden; however, in-
complete silencing of PTTG led to a reduction of tumor
burden, while complete silencing showed nearly complete
eradication of tumors, indicating that PTTG expression
impacts tumor formation and tumor growth [19,21].
Previously, our lab developed a transgenic mouse
model that over-expresses human PTTG cDNA under
the control of Müllerian inhibiting substance type II re-
ceptor (MISIIR). These mice presented with an
increased mass of the corpus luteum as well as an in-
crease in serum LH and testosterone, but failed to gener-
ate visible ovarian tumors [22], possibly due to a weak
promoter that was unable to produce the required level
of PTTG protein to initiate tumorigenesis. In addition,
Abbud et al. [23] generated a PTTG transgenic mouse
under the control of the alpha-subunit of glycoprotein
hormone (αGSU) to target expression to the gonado-
troph cells of the pituitary, resulting in gonadroph
hyperplasia and microadenomas with plurihormal hyper-
plasia, accompanied by prostatic and seminal vesicle
hyperplasia. Tumorigenesis often requires multiple gene
mutations including activation or amplification of onco-
genes, increased growth factors and their receptors, and/
or inactivation of tumor suppressor genes. As such,
PTTG expression by itself may not be sufficient to drive
tumorigenesis and may require a partner gene [24].
Therefore, in our current study, we have selected the
CMV promoter to drive expression of human PTTG
cDNA to produce PTTG transgenic (TgPTTG) mice to
understand the tumorigenic potential of PTTG in vivo.
In addition, we crossbred TgPTTG with p53+/− mice.
TgPTTG mice developed ovarian adenocarcinomas and
adenocarcinoma of the fallopian tube. Crossbreeding of
TgPTTG with p53+/− mice resulted in enhanced tumor
incidence, earlier tumor formation, and carcinomas in
situ of the cervix.
Methods
Construction of CMV-PTTG-EGFP transgene
Human PTTG cDNA was subcloned into the multiple
cloning site of the pEGFP-N3 vector containing the
CMV promoter and EGFP reporter gene. The vector
was restricted using Ase I and Afl II restriction enzymes
(New England BioLabs) by incubating with the vector
for 2 h at 37°C. The restricted vector was run on a 0.7%
agarose gel to isolate the transgene fragment, CMV-
PTTG-EGFP (Figure 1). CMV-PTTG-EGFP was excised
from the gel and purified using a gel extraction kit (Qia-
gen). CMV-PTTG-EGFP was then sequenced to test the
authenticity of the sequence.
Figure 1 Construct of PTTG-EGFP transgene with CMV promoter with primer annealing sites and restriction enzyme sites.
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Mice were housed in a conventional facility with a 12 h
light: 12 h darkness cycle and fed standard chow and
water ad libdum. All animals were treated in accordance
with National Institutes of Health Guidelines for the
Care and Use of Laboratory Animals and approved by
Institutional Animal Care and Use Committee (IACUC)
at the University of Louisville.
Generation of transgenic animals
Transgenic animals were generated in association with
the University of Cincinnati Transgenic Mouse Core
Facility. Transgene DNA was microinjected into the
male pronucleus of FVB 0.5 day old embryos. Embryos
were then transplanted into a pseudo-pregnant female.
Wild type males were bred to positive TgPTTG female
founders. TgPTTG F1 males were bred to wild type
females to establish a colony line.
P53+/− Mice
P53+/− mice on an FVB background were obtained from
Jackson Laboratory. Female p53+/− were crossbred with
male TgPTTG mice from the same founder line
(#71309) to generate TgPTTG/p53+/− mice.
Genotyping and screening of transgenic and p53+/− mice
Mice were tail clipped between 21–28 days of age and
toe tattooed with an ID number. DNA from tail clips
was extracted using PCR Extract-N-Amp kit (Sigma).
PTTG-EGFP genotype was identified via PCR using the
specific primer: PTTG 16182: sense 5’-ACT GAG AAGFigure 2 Genotyping of transgenic mice by PCR using sense PTTG pr
representative genotyping of offspring. Lane 1, 1 kb ladder; lane 2, blank; laACT GTT AAA GC-3’ or PTTG 16207: sense 5’-ACG
AAT TCA TGG CTA CTC TGA TCT ATG T-3’, and
EGFP antisense 23759: 5’- AGA TGA ACT TCA GGG
TCA GC-3’ that specifically amplified the transgene se-
quence (Figure 1). Two PTTG sense primers were used
to verify accuracy of amplification. PCR conditions were
1) 94°C for 5 min, 2) 94°C for 30 sec, 3) 58°C for 30 sec,
4) 72°C for 1 min, 5) steps 2–4 were repeated for
30 cycles, 6) 72°C for 7 min. P53+/− genotype was identi-
fied via PCR using the specific primers according to
Jackson Laboratory protocol: Wild type: sense 5’-ACA
GCG TGG TAC CTT AT-3’, Common: antisense 5’-
TAT ACT CAG AGC CGG CCT -3’, and Mutant: sense
5’-CTA TCA GGA CAT AGC GTT GG-3’. PCR condi-
tions were 1) 94°C for 3 min, 2) 94°C for 30 sec, 3) 64°C
for 1 min, 4) 72°C for 1.5 min, 5) Steps 2–4 repeated for
35 cycles, 6) 72°C for 2 min.
RNA isolation and analysis of transgene expression via
RT-PCR
Tissues were preserved in RNA Later (Sigma) at the
time of sacrificing. Tissues were homogenized in 1 ml of
Trizol (Sigma) and isolated via standard procedures.
Total RNA was quantitated by NanoDrop. One μg of
total RNA was converted to cDNA using a reverse tran-
scription kit (BioRad). Total cDNA was then subjected
to PCR amplification as described above.
Histological analysis
Tissues samples were fixed in 10% neutral buffered for-
malin (Fisher Scientific) overnight at RT. After 24 h,imer 16207 and EGFP antisense primer. (A-B) founders, (C-D) a
nes 3-end, individual mice.







71282 5 (WT) 37 None
71288 5 (WT) 43 None
71305 5 (WT) 42 16
71309 4 (WT) 36 19
WT =wild type.
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tissues were stored at 4°C until processing. Tissues were
embedded in paraffin using standard techniques. Five
micrometer sections were stained with H&E by the
Pathology Core Research Laboratory, University of
Louisville and evaluated by a trained pathologist, Hanan
Farghaly, MD.
Immunofluorescence
Formalin-fixed paraffin embedded tissue sections were
deparaffinized in fresh xylene and rehydrated in a graded
series of ethanol. Antigen retrieval was conducted by in-
cubating the slides in 10 mM sodium citrate (pH 6.0) at
95°C for 20 min then rinsing twice with PBS. Slides were
incubated in 4 drops per section of Image-It FX Signal
Enhancer (Invitrogen) for 30 min in a humidity chamber
and then rinsed with PBS. Slides were blocked with 10%
goat serum (Sigma) in PBS for 1 h followed by anti-
PTTG diluted 1:1,500 in PBS and incubated at 4°C over-
night. Slides were then washed in PBS before application
of a secondary Alexa 594 labeled anti-rabbit (Invitrogen)
diluted 1:500 in PBS containing 1 drop of goat serum
per 5 ml and incubated for 45 min at RT in the dark,
then washed three times with PBS. Images were acquired
on Nikon Eclipse E400 and ACT-1.1 imaging software
(Huntley, IL, USA).
Immunohistochemistry
Formalin-fixed paraffin embedded tissues were deparaffi-
nized in xylene and rehydrated in a decreasing graded
series of ethanol. Antigen retrieval was conducted by in-
cubating the slides in 10 mM sodium citrate (pH 6.0) atFigure 3 Reverse-transcription PCR of specified tissues from WT (W) a
samples. B = blank negative control of reaction mix without template. FT =95°C for 20 min, then rinsed in PBS for 5 min. Slides
were incubated with 0.3% hydrogen peroxide in metha-
nol for 20 min at RT and rinsed three times in PBS for 5
min each. For proliferating cell nuclear antigen (PCNA)
expression, slides were blocked using a Mouse-On-
Mouse (M.O.M.) peroxidase kit (Vector Laboratories)
for 1 h at RT. Blocking solution was poured off and
slides were incubated in M.O.M. diluent for 5 minutes.
PCNA diluted 1:2,000 (Cell Signaling) in SignalStain
antibody diluent (Cell Signaling) was incubated over-
night at 4°C. After washing three times in PBS for 5 min
each, secondary anti-mouse biotinylated IgG from M.O.
M. kit was incubated for 45 min at RT followed by 30
min incubation with streptavidin. After three washes in
PBS for 5 min each, 3, 3’-diaminobenzidine (DAB, Vec-
tor Laboratories) was used to develop color. For CD31,
slides were blocked using Vectastain anti-rabbit Elite
ABC kit (Vector Laboratories) for 1 h at RT and then
incubated with anti-CD31 (1:50, AbCam) in PBS over-
night at 4°C. Vectastain anti-rabbit Elite ABC kit
(Vector Laboratories) and DAB was used to develop
color.
Results
Generation of CMV-PTTG-EGFP transgenic mice
In previous attempts to generate TgPTTG under the
control of promoters MISIIR and αGSU, mice did not
develop visible ovarian or pituitary tumors [22,23].
Therefore, we asked whether the level of PTTG expres-
sion was sufficient to drive tumorigenesis as the level of
PTTG expression was shown to be significant for tumor
growth [19,21]. To this end we selected the non-specific
strong CMV promoter to drive PTTG expression.
Human PTTG cDNA was subcloned into the multiple
cloning site of the N3 expression vector containing the
CMV promoter and a downstream enhanced GFP
(EGFP) marker gene. In order to reduce the transgene
fragment size for ideal transgenic mouse production, the
N3-PTTG was restricted with Ase I and Afl II restriction
enzymes, resulting in the transgene fragment CMV-
PTTG-EGFP (Figure 1). The transgene was sequenced
to ensure authenticity of the sequence. EGFP has beennd transgenic (T) mice. Lane 1, ladder; lane 2, empty; lanes 3-end,
fallopian tube.
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transgene was microinjected into the male pronuclei of
0.5 day old Friend Virus B-Type (FVB) embryos.
TgPTTG founders were identified by PCR screening of
DNA extracted from the tail clip of 34 F0 mice using
two different sense primers located in PTTG and one
antisense primer located in EGFP (Figure 1). This
resulted in the identification of 1 male (#71288) and 3
female TgPTTG founders (#71282, 71305, and 71309;
Figure 2A-B). The founders were crossbred with wild
type (WT) FVB mice and resultant F1 offspring wereFigure 4 Immunofluoroscence of TgPTTG mice for PTTG-EGFP protein
protein and detected with Alexa 594 fluorescent antibody (red). The same
White bar indicates 50 μm.genotyped by PCR (Figure 2C-D). All founders were fertile
and produced an average litter size (Table 1). However, the
male and 1 female founder (#71282) failed to transmit the
transgene to their offspring (F1), suggesting that the trans-
gene did not integrate into the germ line. F1 TgPTTG
males from a single line (founder #71309) were crossbred
with WT females through multiple generations to create
F2-F4 to generate a sufficient number of TgPTTG mice.
TgPTTG males were often aggressive by 6 months of age
and had to be maintained in separate cages. All mice
demonstrated hyperactivity during housing.expression. PTTG antibody was used for immunostaining of PTTG
field viewed with a FITC filter (GFP) and the images were merged.
Figure 5 Immunofluorescence of TgPTTG 8 months old mice
for PTTG-EGFP protein expression. PTTG antibody was used for
immunostaining of PTTG protein and detected with Alexa 594
fluorescent antibody (red). Images were acquired using confocal
microscopy. WT = wild type, FT = fallopian tube. White bar indicates
50 μm.
Figure 6 Immunohistochemistry of 8 months TgPTTG mice with
pre-cancer conditions compared to age-matched WT mice.
PCNA antibody was incubated overnight and then visualized with
DAB (brown color).
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TgPTTG mice were sacrificed at 4, 6, 8, and 10 months
of age along with the age-matched WT controls and tis-
sues were harvested for RNA isolation and immunohis-
tochemistry. Tissues selections were determined by
promoter expression [26] and examined by reverse tran-
scription/PCR of RNA isolated from the ovary, fallopiantube, lung, spleen, liver, and kidney (Figure 3). As expected,
PTTG expression was detected in all of the tissues.
Protein expression of the transgene was determined by
immunofluorescence to determine if expression was
localized to any specific cell type or more broadly dis-
tributed. PTTG primary antibody raised in our labora-
tory [27] was detected with Alexa 594 secondary
antibody (red). Sections were then analyzed by fluores-
cence microscopy using a Texas Red filter for PTTG ex-
pression and GFP filter for EGFP expression. Specificity
of the PTTG antibody to human PTTG vs. murine
PTTG has been addressed previously [22]. Immuno-
fluorescence of the fallopian tube and uterus showed in-
tense staining in the epithelium, while in the ovary,
staining was observed in stromal cells (Figure 4) in
Figure 7 Immunohistochemistry of 8 months TgPTTG mice with cancer compared to age-matched WT mice. PCNA and CD31 antibodies
were incubated overnight and then visualized with DAB (brown color). Red circle indicates in situ tumor.
Table 2 Summary of PCNA and CD31 staining in 8
months old WT and TgPTTG mice
ID# and Tissue PCNA CD31
WT Ovary 1% +
TgPTTG #434 Ovary 35% + +
TgPTTG #436 Ovary 5% + +
WT Cervix 1% NA
TgPTTG #286 Cervix 5% NA
TgPTTG #436 Cervix 5-10% NA
WT Fallopian Tube 0% NA
TgPTTG #365 Fallopian Tube 25% NA
PCNA is percent of positively stained nuclei vs. total. + = < 25%, + + = 25-75%,
+ + + = > 75%.
Fong et al. BMC Cancer 2012, 12:532 Page 7 of 14
http://www.biomedcentral.com/1471-2407/12/5324 months old animals. Lung, spleen, liver, and kidney
showed general non-specific expression of the transgene.
Histology and immunohistochemistry of TgPTTG tissues
Formalin-fixed paraffin embedded tissues were sectioned
and stained with hematoxylin and counterstained with
eosin (H&E). Evaluation of the histology was performed
by a licensed pathologist (HF). Tissues were selected
based on CMV promoter expression [26] to include
liver, kidney, lung, and spleen as well as additional tis-
sues of interest including ovary, fallopian tube, and
uterus. While all tissues were normal in 4 and 6 months
old TgPTTG mice, pre-cancerous conditions (3 out of
15, 20%) and carcinomas (2 out of 15, 13.3%) were
observed at 8 months of age. A total of 15 females were
included in the TgPTTG 8 month old group and were
compared with 11 WT age-matched controls. PTTG-
EGFP expression was confirmed by immunofluorescence
(Figure 5). Pronounced follicular cysts and corpus
luteum were observed in 6 out of 15 (40%) of TgPTTG
females. Pre-cancerous conditions included one female
(#286) having squamous dysplasia with extensive
keratinization at the transformation zone between the
uterus and the cervix (Figure 6), a second female (#365)
developed hyperplasia of the fallopian tube with endo-
thelial atypia (Figure 6), while a third female (#436)
developed low grade dysplasia of squamous epithelium
with acute cervicitis (Figure 6). Inflammation was also
observed in additional females, predominately in the cer-
vix (2 out of 15, 13.3%) and fallopian tube causing dila-
tion (3 out of 15, 20%). Hyperplastic and dysplastic
conditions were confirmed using PCNA staining comparedto age-matched controls [28]. PCNA staining for TgPTTG
#286 revealed 5% positive cells with reverse maturation of
squamous epithelium of the cervix. TgPTTG #365 was
25% positive for PCNA and localized to the epithelial
glands of the fallopian tube. PCNA staining for TgPTTG
#436 cervix was 5-10% positive, localizing to the basal cells
and showed a pattern of reverse maturation. Age-matched
WT fallopian tubes and cervix were negative for PCNA
demonstrating that PTTG increased proliferation. Three
females (20%) developed adenomyosis of the uterus. An
additional two females (13.3%) developed ovarian cancer
(#434, 436; Figure 7). PCNA and CD31 staining were per-
formed to compare proliferation and angiogenesis in
TgPTTG ovarian carcinomas compared to age-matched
WT animals. We decided to use a rating system for CD31
staining, where 1+ means < 25% of tissue was stained, 2+
means 25-75% of tissue was stained, and 3+ means > 75%
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dards. TgPTTG #434 developed ovarian serous adenocar-
cinoma with PCNA staining showed 35% positive area and
CD31 staining was 2+ (Figure 7). TgPTTG #436 developed
a granulosa cell tumor and a follicular cyst with mitotic
figures. In this female, PCNA staining was 5% and CD31
staining was 2+ (Figure 7). Comparatively, age-matched
WT animals showed 1% PCNA staining of the ovary,
which was localized to the granulosa cells of the follicle as
expected, while CD31 staining was 1+ (Figure 7). AFigure 8 Immunofluorescence of TgPTTG 10 months old mice for PTT
immunostaining of PTTG protein and detected with Alexa 594 fluorescent
wild type, FT = fallopian tube, AdC = adenocarcinoma. White bar indicates 5summary of PCNA and CD31 staining patterns are
reported in Table 2. All other tissues were devoid of
visible tumors.
Ten months old TgPTTG group included 10 females
and was compared to 13 WT age-matched controls.
PTTG-EGFP expression was confirmed by immuno-
fluorescence (Figure 8). One female developed a pre-
cancerous serous cyst adenoma of the ovary. Another
developed serous adenocarcinoma of the ovary and fallo-
pian tube (#381, Figure 9), while an additional femaleG-EGFP protein expression. PTTG antibody was used for
antibody (red). Images were acquired using confocal microscopy. WT =
0 μm.
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Figure 9). PCNA staining was 5-10% in both TgPTTG
ovaries and 15% in age-matched WT controls which was
localized to the follicles (Figure 9). CD31 staining was simi-
lar between WT ovaries and TgPTTG ovaries (1+, Figure 9).
Interestingly, PTTG expression was higher in the female
that developed serous adenocarcinoma vs. the female with
the follicular cells tumor (Figure 8). Additionally, 1 out of
20 (5%) of TgPTTG mice developed an ectopic tumor diag-
nosed as a papillary serous adenocarcinoma that was 75%
positive for PCNA and had significant CD31 staining
(3+, Figure 9). Two other females (20%) showed atypia of
epithelial cells of the fallopian tube. A summary of PCNA
and CD31 staining patterns is shown in Table 3. All other
tissues were devoid of visible tumors.Figure 9 Immunohistochemistry of 10 months TgPTTG mice with can
were incubated overnight then visualized with DAB (brown color). Red circTransgene copy number analysis
Although unlikely, the transgene copy number could
have been unstable, and therefore vary among off-
spring. To exclude this possibility, transgene copy
number was assessed to analyze differences between
TgPTTG that developed cancer and those that did
not. A standard curve was generated using the N3
vector containing PTTG (Additional file 1: Figure S1A).
By calculating the size of the vector, a copy number
could be assessed to the standard curve. Then, by tak-
ing 100 ng of genomic DNA isolated from the tail clip,
the gene copy number was extrapolated from the
standard curve as 100 ng of DNA has been reported to
yield 1.67 x 104 diploid cells [29]. We found no differ-
ence in transgene copy number between TgPTTG micecer compared to age-matched WT mice. PCNA and CD31 antibodies
le indicates in situ tumor.
Figure 10 Representative genotyping of offspring from TgPTTG
crossbred to p53+/− mice. Lane 1, ladder; lane 2, empty; lane 3–9,
individual mice samples (ID# 487–495); lane 10 is negative control of
PCR reaction mix without template DNA; and lane 11, positive
control. p53+/− mice were genotyped using recommended primers
from Jackson labs resulting in a robust 400 kb band for p53+ and a
weaker 600 kb band for p53-. Mice were then cross-referenced to
PTTG-EGFP genotype.
Table 3 Summary of PCNA and CD31 staining in 10
months old WT and TgPTTG mice
ID# and Tissue PCNA CD31
WT Ovary 15% + +
TgPTTG #381 Ovary 5-10% +
TgPTTG #383 Ovary 5-10% +
WT Fallopian Tube 0% +
TgPTTG #381 Fallopian Tube 10% + + +
TgPTTG #294 PS AdC 75% + + +
PCNA is percent of positively stained nuclei vs. total. + = < 25%, + + = 25-75%,
+ + + = > 75%. PS AdC = papillary serous adenocarcinoma.
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cancer (Additional file 1: Figure S1B).
Crossbreeding of TgPTTG with p53+/− mice and histology
P53 mutant mice were produced by a targeted neo
cassette insertion into the p53 locus in the laboratory
of Dr. Tyler Jacks at the Center for Cancer Research,
Massachusetts Institute of Technology [30] and are
commercially available through the Jackson Labora-
tory. P53+/− mice have been reported to have an 18%
incidence of adenocarcinomas and a 56% incidence of
sarcomas over a period of 17 months [31]. Based on
the 56 mice we observed (45 p53+/− and 11 p53−/−),
four p53+/− mice (8.9%) developed sarcomas between
3 to 11 months, while nine p53−/− (81.8%) developed
lymphoma and sarcomas at age 9 to 12 weeks before
succumbing to their disease.
Due to the short lifespan of p53−/− mice, p53+/− mice
were chosen for crossbreeding to investigate if a partner
gene would increase the incidence, decrease the onset
time, and/or possibly change the type of cancer in
TgPTTG mice. Two male TgPTTG mice from line
#71309 were crossbred with p53+/− females to maximize
offspring, resulting in generation of F2 (Figure 10).
Accuracy of p53 status of TgPTTG/p53−/− and
TgPTTG/p53+/− was confirmed by sequencing genomic
DNA. PTTG-EGFP expression was analyzed by im-
munofluorescence and was higher in TgPTTG/p53−/−
tumors than TgPTTG/p53+/− (Figure 11). Due to tumor
burden, three mice necessitated premature euthaniza-
tion. Of the three, one TgPTTG/p53−/− mouse (#450)
developed two teratocarcinomas at 7 weeks of age, while
a second mouse developed lymphoma and two sarcomas
at 11 weeks of age (#448, Figure 12). Comparatively, p53−/−
mice develop lymphoma and sarcomas at 12 weeks (9 of
11). The third mouse was TgPTTG/p53+/− between
TGPTTG and p53+ that developed adenocarcinoma of the
fallopian tube and leiomyosarcoma with mitotic figures at 7
months of age (#272, Figure 12). PCNA and CD31 analysis
was performed in these tissues. PCNA was 90% in the
teratocarcinoma as well as TgPTTG/p53−/− sarcoma and99% in the TgPTTG/p53+/− leiomyosarcoma (Figure 12).
All tumors showed CD31 staining of 1+ (Figure 12).
TgPTTG/p53+/− mice aged to 8 months included 10
females. Of the TgPTTG/p53+/− females aged to 8
months, 4 out of 10 (40%) had severe dysplasia of the
cervix resulting in carcinomas in situ (Figure 12) along
with 1 out of 10 (10%) developing a sarcoma. PCNA
staining for cervical carcinomas in situ showed 10%
positive area with reverse maturation and 2+ microvessel
formation. PCNA showed 99% positive area in all sarco-
mas, congruent with the highly aggressive nature of this
tumor type.
TgPTTG/p53+/− mice aged to 10 months included 8
females. Five out of 8 (63%) females showed focal to se-
vere cervical dysplasia resulting in carcinomas in situ,
and 3 out of 8 (38%) showed dilation of the fallopian
tube. Two out of 8 (25%) developed high grade leiomyo-
sarcomas (Figure 12). All TgPTTG/p53+/− sarcomas
were 99% positive for PCNA and had significant micro-
vessel formation (CD31 staining 3+) determined by
CD31 (Figure 12). Comparatively, p53+/− mice developed
sarcomas between 11 to 12 months of age (2 of 28, 7%).
The timeline of tumor developments in TgPTTG, p53+/−,
and TgPTTG/p53+/− is summarized in Figure 13.
Discussion
PTTG has been shown in pituitary tumors to have the
properties of a transforming gene activated during the
Figure 11 Immunofluorescence of TgPTTG/p53+/− mice for PTTG-EGFP protein expression. PTTG antibody was used for immunostaining of
PTTG protein and detected with Alexa 594 fluorescent antibody (red). Images were acquired using confocal microscopy. FT = fallopian tube.
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http://www.biomedcentral.com/1471-2407/12/532early stages of neoplastic transformation, changing the
cells from a normal phenotype to hyperplastic [13].
Based on this information, a transgenic mouse expres-
sing PTTG under the control of αGSU promoter to tar-
get the expression to the gonadotroph cells of the
pituitary was created [23]. This resulted in gonadroph
hyperplasia and microadenomas with plurihormal hyper-
plasia, accompanied by prostatic and seminal vesicle
hyperplasia, demonstrating that PTTG was a functional
transforming oncogene. Since PTTG is a prominent
oncogene in pituitary tumors, many investigators have
identified PTTG in several other endocrine-related
tumors. Its expression has been detected in endometriodcarcinomas and in hyperplastic endometria [32]. In
addition to being cloned from ovarian tumors, PTTG
has been identified in various ovarian tumor tissues but
not in normal ovary [11]. In addition, a mouse xenograft
model of ovarian cancer showed that PTTG was crucial
for tumor development [19]. Therefore, previously our
lab developed a transgenic mouse model that expresses
human PTTG cDNA under the control of MISIIR. These
mice presented with an increased mass of the corpus
luteum as well as an increase in the serum LH and tes-
tosterone. However, despite PTTG expression in the
ovary and testes, these animals developed cystic glandu-
lar hyperplasia but failed to develop visible ovarian
Figure 12 Immunohistochemistry of TgPTTG/p53+/− mice at various ages. PCNA and CD31 antibodies were incubated overnight then
visualized with DAB (brown color).
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http://www.biomedcentral.com/1471-2407/12/532adenocarcinomas [22], possible due to a weak promoter
that was unable to produce the required level of PTTG
protein to initiate tumorigenesis. However, we also asked
if a partner gene was necessary to complete tumorigen-
esis as it often requires multiple gene mutations includ-
ing activation or amplification of oncogenes, increased
growth factors and their receptors, and/or inactivation
of tumor suppressor genes, and therefore PTTG expres-
sion by itself may not be sufficient to drive tumorigen-
esis and may require a partner gene [24].
Therefore, in our current study to understand the
tumorigenic potential of PTTG, we generated a trans-
genic mouse that constitutively overexpresses PTTGunder the control of the non-specific CMV promoter to
strengthen PTTG expression as the level of PTTG is
critical for tumorigenesis [19,33]. By using this approach,
we were able to generate ovarian tumors in transgenic
animals as early as 8 months of age (Figure 7) and con-
tinued to observe them at 10 months (Figure 9), albeit at
a low incidence of ~17%. It is interesting that although
the CMV promoter is a non-specific promoter, ovarian
and fallopian tube tumors and papillary serous adenocar-
cinomas were the only observed tumor types, perhaps
due to the site of integration. However, PTTG also has
transactivation activity through the presence of Src-
homology 3 (SH3) domains located in the proline-rich
Figure 13 Timeline summary of pre-cancerous and cancer results for TgPTTG (red), p53−/− (green), p53+/− (green), and TgPTTG/p53+/−
(blue).
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http://www.biomedcentral.com/1471-2407/12/532regions of the C-terminus [34]. As such, PTTG increases
the excretion of bFGF [11], which itself can increase ovar-
ian cancer invasion [35]; therefore, PTTG itself may not
directly induce tumorigenesis but acts indirectly on tissues
expressing a higher level of bFGF, such as the ovary, fallo-
pian tube, and cervix [36-38] to increase angiogenesis and
stimulate expression of other activator genes, such as Ets-1
and urokinase-type plasminogen activator to promote
tumor progression.
Since our incidence of tumor formation was ~17%,
we cross-bred our TgPTTG mice with p53 mutant
(p53+/−) mice with the assumption that p53+/− would en-
hance the incidence. Using this approach, TgPTTG/p53+/−
animals resulted in earlier tumor development than PTTG
or p53+/− alone (Figure 13) and increased the incidence of
high grade leiomyosarcomas from 7% in p53+/− mice to
14% in TgPTTG/p53+/−. We also noted a significant inci-
dence of cervical carcinomas of 63% in TgPTTG/p53+/−.
Most cases of cervical cancer in women are due to human
papilloma virus (HPV) infections that cause inactivation of
p53 and Rb, mutations that mainly affect the squamous epi-
thelium along the transformation zone as HPV infections
require cells that are proliferating [39]. In our TgPTTG
mice, we noticed a reverse maturation of the basal squa-
mous epithelium coupled to dysplasia. As PTTG increases
cell proliferation as observed by PCNA staining, PTTG
could serve to prime the basal epithelium, which could
make these particular cells more susceptible to further neo-
plastic transformation due to alterations of additional
genes, such as p53. We also noted teratocarcinomas in
TgPTTG/p53−/−. While little is known about the genetic
contributions to teratocarcinomas, the field theory states
that normal germ cells that are placed in an environment
that allows expression of the cancer phenotype have the po-
tential to become cancerous [40]. Constitutive overexpres-
sion of PTTG may alter the micro environment through
enhanced secretion of growth factors, and thus allow nor-
mal cells to proliferate more rapidly causing transformationof normal cells to become tumorigenic leading to the for-
mation of tumors, such as teratocarcinomas.
Conclusions
In our studies, we showed that PTTG is a functional onco-
gene that is capable of initiating transformation of normal
tissue to dysplastic. Furthermore, a high expression level of
PTTG was capable of inducing tumorigenesis in the ovary
and other tissues leading to tumorigenesis. Coupling of
TgPTTG with mutant p53 led us to conclude that the early
neoplastic events (normal to dysplastic) were independent
of p53 as the additional mutation did not enhance inci-
dence of ovarian cancer; however overexpression of PTTG
and loss of p53 function reduced the time of development
of certain cancers, including sarcoma.
Additional file
Additional file 1: Figure S1. Transgene copy number analysis of
TgPTTG mice that developed cancer and TgPTTG mice that did not. (A)
Standard curve generated from N3 cloning vector containing PTTG in the
multiple cloning site. (B) Real-time PCR analysis of transgene copy
number extrapolated from standard curve plotted as average ± SD.
TgPTTG mice were selected from 8 months – 10 months. N = 3 for no
cancer, N = 6 for cancer.
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